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Abstract
 
Spatiotemporal aspects of filovirus entry and release are poorly understood. Lipid rafts act as
functional platforms for multiple cellular signaling and trafficking processes. Here, we report
the compartmentalization of Ebola and Marburg viral proteins within lipid rafts during viral
assembly and budding. Filoviruses released from infected cells incorporated raft-associated
molecules, suggesting that viral exit occurs at the rafts. Ectopic expression of Ebola matrix
protein and glycoprotein supported raft-dependent release of filamentous, virus-like particles
(VLPs), strikingly similar to live virus as revealed by electron microscopy. Our findings also re-
vealed that the entry of filoviruses requires functional rafts, identifying rafts as the site of virus
attack. The identification of rafts as the gateway for the entry and exit of filoviruses and raft-
dependent generation of VLPs have important implications for development of therapeutics
and vaccination strategies against infections with Ebola and Marburg viruses.
Key words: Filovirus • Ebola • rafts • budding • VLP
 
Introduction
 
The filoviruses Ebola (EBOV) and Marburg (MBGV) are
two of the most pathogenic viruses in humans and nonhu-
man primates (1) which cause a severe hemorrhagic fever
(2). The mortality rates associated with infections of Ebola
or Marburg virus reach as high as 70–80% (1, 2). Although
natural outbreaks have been geographically restricted so far,
limited knowledge of the mechanisms of pathogenicity, po-
tential of aerosol transmission (3), unknown natural reser-
voir, and lack of immunological and pharmacological thera-
peutic measures pose a challenge to classification of the
public health threat of Marburg and Ebola viruses. Despite
recent advances in vaccine development in certain animal
models (4–7), substantial obstacles need to be overcome be-
fore such vaccines could qualify for human clinical trials (8).
Efforts to develop therapeutics against Ebola and Marburg
have been hampered, in part, by limited knowledge of the
mechanism of action of viral proteins and the poor under-
standing of the process of filovirus entry and budding at the
molecular level. Understanding the nature of interactions
between filoviruses and the host, both at the cellular and
organism levels, is essential for successful development of
efficacious prophylactic and therapeutic measures.
Both entry and release of enveloped virus particles are
dependent on an intimate interaction with components of
the cellular membranes. While the plasma membrane was
initially envisioned as a fluid, randomly arranged lipid bi-
layer with incorporated proteins, recent advances demon-
strate that this important cellular barrier is more sophisti-
cated and dynamic than portrayed by the original simplistic
models. Cholesterol-enriched regions in the lipid bilayer
have been recently defined that adopt a physical state re-
ferred to as liquid-ordered phase (l
 
o
 
) displaying reduced flu-
idity and enhanced ability for lateral and rotational mobility
(9, 10). These low density, detergent-insoluble micro-
domains, known as lipid rafts, accommodate a selective set
of molecules such as gangliosides, glycosphingolipids, gly-
cosylphosphatidylinositol (GPI) anchored proteins, and
signaling proteins such as Src family kinases, T and B cell
receptors, and phospholipase C (9, 11–14). By virtue of
these unique biochemical and physical properties, lipid rafts
 
✪
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function as specialized membrane compartments for chan-
neling certain external stimuli into specific downstream
pathways (15, 16), act as platforms in cell–cell interactions
(17, 18), and have also been implicated in membrane traf-
ficking (10, 19). Lipid rafts are believed to perform such di-
verse functions by providing a specialized microenviron-
ment in which the relevant molecules for the initiation of
the specific biological processes are partitioned and concen-
trated (11). Such compartmentalization may help the sig-
nals achieve the required threshold at the physiological
concentrations of the stimuli. Partitioning in lipid rafts can
also be perceived as a measure to perform functions in a
more specific and economic manner while keeping distinct
pathways spatially separated.
Several lines of evidence suggest a role for cholesterol-
enriched lipid rafts in host-pathogen interactions. Choles-
terol has been shown to play a critical role for the entry of
mycobacterium into macrophages (20). Multiple compo-
nents of influenza virus (21), measles virus (22), and HIV
(23, 24) have been shown to localize to lipid rafts. These
lipid platforms have also been implicated in the budding of
HIV and influenza virus (21, 23). Therefore, rafts, as tightly
regulated specialized domains, may represent a coordina-
tion site for the intimate interactions of viral proteins re-
quired for the assembly and budding process. While in-
volvement of rafts in virus entry has been postulated (25),
supporting data on this issue have been reported only for
HIV infection of certain T cell lines (26).
Here, using a variety of biochemical and microscopic ap-
proaches, we demonstrate the compartmentalization of
Ebola and Marburg viral proteins in lipid rafts during viral
assembly and budding. Our findings also show that the en-
try of filoviruses into cells is dependent on functional rafts.
Thus, this study provides a deeper understanding of the
molecular mechanisms of filovirus pathogenicity at the cel-
lular level and suggests raft integrity and/or raft compo-
nents as potential targets for therapeutic interventions. We
also report, for the first time, the raft-dependent formation
of Ebola-based, genome-free, virus-like particles (VLPs)
 
*
 
,
which resemble live EBOV in electron micrographs. Such
VLPs, besides being a research tool, could be potentially
useful as vaccines against filovirus infections, or as vehicles
for the delivery of a variety of antigens artificially targeted
to the rafts.
 
Materials and Methods
 
Plasmids, Transfections, Western Blot Analysis, and GM1 Blot.
 
cDNAs encoding EBOV-Zaire glycoproteins (GPs) and VP40 as
well as MBGV Musoke GP were cloned in pWRG7077 mam-
malian expression vector. 293 T cells were transfected using a cal-
cium phosphate transfection kit (Edge Biosystems) according to
manufacturer’s instructions. Western blot analysis was performed
using as primary antibodies anti-EBOVGP mAb 13F6 (27), anti-
Marburg GP mAb (5E2), anti-EBOV-VP40 mAb, or a guinea
pig anti-Marburg antibody, followed by blotting with HRP-con-
jugated secondary antibodies and signals were detected by en-
hanced chemiluminescence. GM1 was detected in lysates or im-
munoprecipitates by spotting on a nitrocellulose membrane after
boiling in SDS, followed by blocking of the membranes and blot-
ting with HRP-conjugated CTB and detection by ECL.
 
Preparation of Detergent Insoluble Fractions and Lipid Rafts.
 
Lipid rafts were prepared after lysing the cells in lysis buffer con-
taining 0.5% Triton X-100 as described previously (13). Raft and
soluble fractions were then analyzed by immunoblotting. In some
experiments (see Fig. 3 A), detergent-insoluble fractions were ex-
tracted without ultracentrifugation as described previously (24).
Briefly, cells were pelleted and lysed in 0.5% Triton X-100 lysis
buffer. After removing the lysate (soluble fraction), the pellet was
washed extensively and SDS sample buffer added to the pellet
(insoluble fraction). Soluble and insoluble fractions were analyzed
by SDS-PAGE and immunoblotting.
 
Cell Culture, Infections, Virus, and VLP Purification.
 
PBMCs were
isolated by density centrifugation through Ficoll-Paque (Amer-
sham Pharmacia Biotech) according to the manufacturer’s in-
structions. PBMCs were cultured in RPMI/10% FBS for 1 h at
37
 

 
C and 5% CO
 
2
 
 after which nonadherent cells were removed.
HEPG2 cells (American Type Culture Collection) were cultured
to confluency with complete RPMI 1640 before use. Monocyte-
derived macrophages, HEPG2 cells, and Vero-E6 cells were in-
fected at a multiplicity of infection of 1 with either Ebola-Zaire
or Marburg Musoke virus for 50 min at 37
 

 
C, 5% CO
 
2
 
. Nonad-
sorbed virus was removed from cells by washing monolayers
twice with PBS followed by addition of fresh complete medium
for an additional 24–48 h. Purification and inactivation of Mar-
burg virus was performed as described previously (7). Briefly,
Vero-E6 cells were infected with MBGV and supernatant was
harvested 6–7 d after infection. The medium was clarified and vi-
rus concentrated by polyethylene glycol precipitation. After cen-
trifugation at 10,000 
 
g
 
 for 30 min, pellets were resuspended in
Tris buffer, and layered atop 20–60% sucrose gradients and cen-
trifuged at 38,000 rpm for 4 h. The visible virus band was col-
lected. Samples were inactivated by irradiation (10
 
7
 
 R, 
 
60
 
Co
source) and tested for absence of infectivity in cell culture before
use. For preparation of VLPs, supernatants were collected 60 h
after transfection, overlaid on 30% sucrose, and ultracentrifuged
at 26,000 rpm for 2 h. Pelleted particulate material was recovered
in PBS and analyzed by immunoblotting or electron microscopy.
As a further purification step, in some experiments, this particu-
late material was loaded on a step gradient consisting of 80%,
40%, and 30% sucrose. After 2-h centrifugation at 26,000 rpm,
the VLPs were recovered from the interface of 80% and 40% su-
crose layers.
 
Plaque Assays.
 
Infectious Ebola and Marburg virions were
enumerated using a standard plaque assay as described previously
(6). Briefly, culture supernatants were serially diluted in EMEM.
100 
 

 
l of each dilution were added to wells of Vero-E6 cells in
duplicate. Virus was allowed to adsorb for 50 min. Wells were
then overlaid with 1
 

 
 EBME and 0.5% agarose. Plates were in-
cubated at 37
 

 
C, 5% CO
 
2
 
 at which time a second overlay of 1
 

 
EBME/0.5% agarose and 20% neutral red was added to each
well, incubated for an additional 24 h and plaques were counted.
 
Cell Staining and Confocal Microscopy.
 
293T cells were stained
with indicated antibodies to viral proteins followed by Alexa-647
conjugated secondary antibodies (Molecular Probes). Rafts were
visualized by staining of GM1 with Alexa-488 conjugated CTB
and in some experiments with rhodamine-conjugated CTB (see
Fig. 2 B). Staining was performed on live cells on ice for 20 min.
 
*
 
Abbreviations used in this paper:
 
 GP, glycoprotein; GPI, glycosylphosphati-
dylinositol; TrfR, transferrin receptor; VLP, virus-like particle.
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Cells were then washed with PBS, fixed in 3% paraformaldehyde,
washed, and mounted on microscopy slides. Images were col-
lected using the Bio-Rad Laboratories Radiance 2000 system at-
tached to a Nikon E600 microscope. Alexa-488 immunostain
was excited using 488 nm light from a Krypton-Argon laser and
the emitted light was passed through an HQ515/30 filter. Fluo-
rescence from the Alexa-647 dye was excited by 637 nm light
from a red diode laser and collected after passing through an
HQ660LP emission filter. The lasers were programmed to scan
over successive focal planes (0.25–0.5 
 

 
m intervals) at 50 lines per
second. Lasersharp software was used to control the confocal sys-
tem and to reconstruct individual focal planes into three-dimen-
sional renderings.
 
Electron Microscopy.
 
Portions of particulate material were ap-
plied to 300-mesh, nickel electron microscopy grids precoated
with formvar and carbon, treated with 1% glutaraldehyde in PBS
for 10 min, rinsed in distilled water, and negatively stained with
1% uranyl acetate. For immunoelectron microscopy, fractions
were processed as described previously for fluid specimens (28).
Briefly, fractions were applied to grids and immersed for 45 min
in dilutions of mAbs against EBOV GP. Normal mouse ascetic
fluid was tested in parallel. Grids were washed with the TRIS
buffer and incubated for 45 min with goat anti–mouse IgG la-
beled with 10-nm gold spheres (Ted Pella, Inc.). Grids were
washed in PBS, and fixed in 1% glutaraldehyde. After fixation,
grids were rinsed in drops of distilled water and negatively stained
with 1% uranyl acetate. For preembedment staining, cells were
stained with anti-Ebola GP mAb followed by gold anti–mouse
Ab, fixed with 2% glutaraldehyde in Millonig’s buffer (pH 7.4)
for 1 h, and postfixed in 1% uranylacetate, dehydrated, and em-
bedded in POLY/BED 812 resin (Polysciences). Resin was al-
lowed to polymerize for 16 h at 60
 

 
C, ultrathin sections (
 

 
80
nm) were cut, placed on 200-mesh copper electron microscopy
grids, and negatively stained. Stained grids were examined with a
JEOL 1200 EX transmission electron microscope at 80 kV.
 
Online Supplemental Material.
 
The cells shown in supplemen-
tal Videos 1–4 were stained, fixed, and imaged using confocal
microscopy as described above and in the video legends.  3-D re-
constructions were created using Lasersharp software (Bio-Rad
Laboratories).  Montage videos of successive optical planes (sup-
plemental Videos 1 and 3) and 3-D rotational views (supplemen-
tal Videos 2 and 4) were created using Metamorph imaging soft-
ware (Universal Imaging Corp.). 
 
Results
 
Association of Filovirus GPs with Lipid Rafts.
 
Targeting of
membrane-spanning proteins to lipid rafts is commonly
governed by dual acylation of cysteine residues at the cyto-
solic end of the transmembrane domains (24, 29). The
filovirus envelope GPs contain such acylation signals in
their transmembrane domains (1) and palmitoylation of
Ebola GP has been recently reported (30). By transient ex-
pression of the filovirus envelope GPs in 293T cells and
subsequent extraction of rafts by sucrose gradient ultracen-
trifugation (13), we examined whether these GPs localize
to lipid rafts. As shown in Fig. 1 A and B, a significant frac-
tion of Ebola and Marburg GPs were found to reside in
rafts. In contrast, an Ebola GP, mutated at cysteine residues
670 and 672 (Ebo-GP
 
C670/672A
 
), the putative palmitoylation
sites, failed to localize to the rafts (Fig. 1 B). Lipid rafts are
highly enriched in ganglioside M1 (GM1) which can be
detected by its specific binding to cholera toxin B (CTB)
(31, 32). As a control for the quality of raft preparations, we
analyzed the soluble and raft fractions for the presence of
GM1 by spot blots using HRP-conjugated CTB and dem-
onstrated that GM1 was exclusively found in the raft frac-
tions (Fig. 1 A and B, bottom panels). The association of
GPs with detergent insoluble fraction was dependent on
cholesterol since pretreatment with methyl-
 

 
-cyclodextrin
Figure 1. Localization of filovirus GPs in lipid rafts. 293T cells were
transfected with Marburg GP (A), Ebo-GPwt, or Ebo-GPC670/672A (B),
or a control plasmid, rafts were prepared by ultracentrifugation and GP
was detected by immunoblotting. GM1 was detected by blotting with
HRP-CTB in the corresponding fractions spotted on a nitrocellulose
membrane, as a control for the quality of raft preparation. (C) 48 h after
transfection of 293T cells with Ebola GP, a portion of cells were treated
for 20 min with 10 mM methyl--cyclodextrin (MCD) and another
portion was left untreated. Raft and soluble fractions were prepared and
analyzed by immunoblotting for GP (top panel) and for the raft-excluded
protein TrfR (bottom panel).
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(M
 

 
CD), a drug that depletes the membrane of cholesterol
(33), resulted in almost complete removal of Ebola GP
from rafts (Fig. 1 C, top panel). As a further control, we
showed that transferrin receptor (TrfR), a molecule ex-
cluded from rafts (31), was only found in the soluble frac-
tion (Fig. 1 C, bottom panel). To confirm the raft localiza-
tion of Ebola and Marburg GP on intact cells, we also
performed confocal laser microscopy on 293T cells that
were transfected with Ebola or Marburg GP and costained
with anti-GP antibodies and CTB. As shown in Fig. 2 A, a
substantial portion of both of the GPs were found to colo-
calize with GM1 in large patches on the plasma membrane,
confirming the raft association of both GPs on intact cells.
Videos visualizing 25 sections through the cells, as well as
three-dimensional (3-D) reconstruction of the cells by
compiling data from these sections are available as supple-
mental data on the web (Videos 1 and 2). Confocal micros-
copy again showed that the membrane domains visualized
by CTB staining were devoid of the raft excluded TrfR
(Fig. 2 B).
 
Filoviral Proteins Associate with Lipid Rafts in Cells Infected
with Live Virus.
 
Two of the primary target cells of filovi-
ruses are monocyte/macrophages and hepatocytes (1).
Thus, to examine the localization of EBOV and MBGV
proteins with respect to lipid rafts during infection with
live virus, primary human monocytes, HepG2 hepato-
cytes, and also Vero-E6 cells (commonly used to propa-
gate filoviruses) were used as target cells. Human mono-
cytes were infected with the Musoke strain of MBGV,
after 24-h detergent-insoluble and detergent-soluble frac-
tions were separated by centrifugation (24). As shown in
Fig. 3 A, a major portion of viral proteins was detected in
the detergent-insoluble fraction (I) 24 h after infection.
We then performed similar experiments with HepG2 cells,
infected with EBOV-Zaire95, and prepared lipid rafts by
sucrose gradient ultracentrifugation. Similar to Marburg,
Ebola VP40, and GP were detected mainly in lipid rafts 24 h
after infection of HepG2 hepatocytes (Fig. 3 B). To fur-
ther confirm the accumulation of filovirus proteins in lipid
rafts in intact cells, Vero-E6 cells, infected with EBOV,
were fixed, irradiated, and costained with anti-Ebola anti-
body and CTB. As shown in Fig. 3 C, we observed a
striking colocalization of viral proteins with the lipid rafts
in intact Ebola-infected cells (Videos 3 and 4), suggesting
that viral proteins assemble at lipid rafts during the course
of viral replication.
 
Ebola and Marburg Virions Incorporate the Raft Molecule
GM1 during Budding.
 
To determine whether the virus
was released through lipid rafts, we analyzed EBOV from
culture supernatants of infected cells for the presence of the
raft marker GM1. Enveloped viruses bud as virions sur-
rounded by the portion of the plasma membrane at which
assembly takes place (34). Release of virions through lipid
rafts would therefore result in incorporation of raft-associ-
ated molecules in the viral envelope, thus identifying virus
budding from the rafts. As shown in Fig. 4 A, EBOV im-
munoprecipitated with anti-Ebola GP antibody from su-
pernatant of infected Vero-E6 cells contained readily de-
tectable levels of GM1. We also analyzed inactivated
Marburg virus that had been purified by ultracentrifugation
for the incorporation of GM1 and demonstrated that GM1
was detectable in MBGV (Fig. 4 B, bottom panel). In con-
Figure 2. Colocalization of
filovirus GPs with GM1 on in-
tact cells. (A) 293T cells were
transfected with the indicated
GP, and stained at 4C with
Alexa488-CTB (green) and anti-
GP mAb followed by Alexa-647–
conjugated anti–mouse antibod-
ies (red), cells were fixed and im-
aged using confocal microscopy.
Colocalization is represented by
yellow appearance in the overlay
(right panels). A 3-D reconstruc-
tion of the compiled data from
25 sections of an Ebo-GP–trans-
fected cell is also shown. (B)
293T cells were concurrently
stained at 4C with Alexa-488–
conjugated anti-TrfR antibody
(green) and rhodamine-CTB
(red), fixed and analyzed by con-
focal microscopy. No colocaliza-
tion between these two mole-
cules was observed, evident by
the lack of yellow appearance in
the overlay. Two representative
cells are shown.
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trast, the raft-excluded protein TrfR was not incorporated
in Marburg virions (Fig. 4 B, middle panel). Taken to-
gether, these data strongly suggested that both viruses exit
cells through lipid rafts.
 
Release of GM1-containing Particles by Ectopic Expression of
Ebola Proteins.
 
To further test the hypothesis that filovi-
ruses assemble and bud via lipid rafts, we transiently ex-
pressed viral proteins and searched for GM1-containing vi-
rus-like particles (VLPs). Several viral proteins have been
shown to support the formation of VLPs (35–37). In trans-
fected 293T cells, Ebola GPwt, GP
 
C670/672A
 
, and VP40
were readily detected in cell lysates when each protein was
expressed individually (Fig. 5 A, panels 1 and 3, lanes 2, 3,
and 4). However, when VP40 and GP were coexpressed,
little GP and almost no VP40 were found associated with
the cells 60 h after transfection (Fig. 5 A, panels 1 and 3,
lane 5). To examine the viral proteins released from the
cells, culture supernatants were cleared of cells, and partic-
ulate material was purified by ultracentrifugation 
 

 
30%
sucrose cushion. As shown in Fig. 5 A (panels 2 and 4,
lanes 2–4), large amounts of GPwt and lesser quantities of
GP
 
C670/672A
 
 or VP40 were detected in the particulate mate-
rial from the supernatants of singly transfected cells. Inter-
estingly, coexpression of GPwt and VP40, directed the
majority of both proteins into the supernatant (Fig. 5 A,
panels 2 and 4, lane 5). Next, we tested if the released par-
ticles incorporated the raft-associated molecule GM1.
Anti–Ebo-GP immunoprecipitates from the supernatants
of the cells transfected with GPwt or GPwt
 

 
VP40, but
not GP
 
C670/672A
 
, contained GM1 (Fig. 5 A, panel 5), sug-
gesting that the release of these particles takes place
through the rafts. We performed a second step of purifica-
Figure 3. Localization of filovirus proteins in lipid rafts in infected cells. (A)
Primary human monocytes were infected with MBGV. After 24 h cells were ly-
sed in 0.5% Triton X100 and detergent-soluble (S) and -insoluble (I) fractions
were separated by centrifugation, samples were irradiated (2  106 R), and ana-
lyzed by immunoblotting with a guinea pig anti-MBGV antibody to detect viral
proteins NP and VP35/VP40 (lanes 3 and 4); lanes 1 and 2, uninfected control;
lane 5, inactivated MBGV (1 g). NS, nonspecific band. (B) HepG2 hepato-
cytes were infected with EBOV-Zaire, lysed, irradiated (6  106 R), and rafts
(R) and soluble (S) fractions were prepared by ultracentrifugation 24 h after in-
fection. Ebola GP and VP40 were detected by immunoblotting. (C) Ebola-
infected Vero E6 cells were irradiated (4  106 R), fixed and stained for Ebola
virus (red) and GM1 (green) at 4C and imaged by confocal microscopy. (Left
panel) single section; (right panel), 3-D reconstruction of the compiled data.
Figure 4. Incorporation of GM1 in released filovirus virions. (A)
Ebola virus was immunoprecipitated from supernatant of infected
Vero-E6 cells (lane 2), or uninfected cells as control (lane 1), using
anti-GP mAb. After irradiation (2  106 R), a fraction of immuno-
precipitate (IP) was spotted on nitrocellulose membrane and blotted
with HRP-conjugated CTB to detect GM1 (bottom panel). Another
portion of the IP was analyzed by SDS-PAGE and immunoblotting
with anti-GP mAb (top panel). (B) MBGV (1 g), prepared by ultra-
centrifugation and inactivated by radiation (107 R), was analyzed for
the presence of GM1, TrfR, and GP in a similar fashion. As control,
rafts and soluble fractions from untransfected 293T cells were used.
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tion on these particles using a sucrose step gradient to sep-
arate the virus-like particles from the cell debris. The low-
density fraction floating between 40 and 80% sucrose was
then analyzed by Western blot analysis. As shown in Fig. 5
B, these particles contained GM1 but totally excluded
TrfR, further confirming the release of particles through
lipid rafts.
 
Particles Formed by EBOV GP and VP40 Display the Mor-
phological Characteristics of Ebola Virus.
 
We determined the
composition and morphology of these particles by exami-
nation of the purified particulate material using electron
microscopy. Interestingly, most of the particles obtained
from the supernatants of the cells cotransfected with GPwt
and VP40 displayed a filamentous morphology strikingly
similar to filoviruses (Fig. 6 A and B) (28, 38). In contrast,
the material obtained from cells transfected with GPwt,
GP
 
C670/672A
 
, or VP40 only contained small quantities of
membrane fragments, likely released during cell death (data
not shown). The VLPs generated by GP and VP40 were
released at a high efficiency. Typically, we achieve a titer
of 0.5–1.0 
 

 
 10
 
6
 
 VLPs/ml 2–3 d after transfection. The
VLPs have a diameter of 50–70 nm and are 1–2 
 

 
m in
length (Fig. 6). This is similar to the length range of Ebola
virions found in cell culture supernatants after in vitro in-
fection (28). The shorter diameter of VLPs (as compared
with 80 nm for EBOV) may be due to the lack of ribonu-
cleoprotein complex. We observed all types of morpholo-
gies described for filoviruses such as branched, rod-, U-,
and 6-shaped forms (1, 28) among these particles (Fig. 6).
In addition, the VLPs were coated with 5–10 nm surface
projections or “spikes” (Fig. 6), characteristic for EBOV
(1, 28). Immunogold staining of the VLPs with anti-Ebola
GP antibodies demonstrated the identity of the spikes on
the surface of the particles as Ebola GP (Fig. 6 B). To visu-
alize the process of the release of the VLPs, cells transfected
with GP and VP40 were analyzed by electron microscopy
after preembedment immunogold staining. Fig. 6 C shows
a typical site of VLP release, where a large number of par-
ticles that stain for GP exit through a small region of the
plasma membrane (indicated by arrows). These sites of
VLP release have an average diameter of 
 

 
1 
 

 
m. Given
the incorporation of GM1 in the VLPs (Fig. 5) these parti-
cle-releasing platforms most likely represent coalesced lipid
raft domains.
 
Entry of EBOV Is Dependent on the Integrity of Lipid
Rafts.
 
Having established a critical role for lipid rafts in vi-
rus release, we sought to investigate if filoviruses utilize the
same gateway for entry. To examine the role of lipid rafts in
filovirus entry, the effects of raft-disrupting agents filipin and
nystatin on Ebola infection were explored. Brief treatment
of cells with filipin (0.2 
 

 
g/ml, 30 min) before infection re-
sulted in a significant inhibition of EBOV infection evident
by reduced viral titer 48 h after infection (Fig. 7). Similar re-
sults were also obtained with another cholesterol-destabiliz-
ing agent nystatin (Fig. 7). This effect was not due to a gen-
eral cytotoxic effect by the drugs as cells were shown to be
viable by trypan blue exclusion (data not shown). To rule
out the possibility of a persistent effect of this brief drug
treatment on the viral replication, we let an aliquot of the
cells recover in medium (for 4 h) after filipin treatment be-
fore infecting them with EBOV. As shown in Fig. 7 (Fil-
ipin
 
→
 
recovery), these cells could produce large amounts of
virus, ruling out the possibility of late effects of the drug on
viral replication. In fact, in cells recovered from raft disrup-
Figure 5. Release of Ebola GP and VP40 as GM1-containing particles.
(A) 293T cells were transfected with the indicated plasmids, supernatants
were cleared from floating cells by centrifugation, and particulate material
was pelleted through 30% sucrose by ultracentrifugation. The individual
proteins were detected in the cell lysates and in the particulate material
from supernatant by immunoblotting (IB). A fraction of cleared superna-
tant was subjected to immunoprecipitation using anti-GP mAb and ana-
lyzed for the presence of GM1 (bottom panel) as described in the legend
to Fig. 1. (B) The particulate material from cells transfected with
GPVP40 was further purified on a sucrose step gradient and the low
density fraction was analyzed for the presence of VP 40 (top panel), TrfR
(middle panel), and GM1 (bottom panel). Rafts and soluble fractions from
untransfected 293T cells were used as control.
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tion the infection was even more efficient. This might be
due to a synchronizing effect by reorganization of the mi-
crodomains resulting in a more efficient entry of the virus
into a larger number of cells. We also considered the possi-
bility that raft disruption may interfere with virus attach-
ment rather than entry. However, titration of the virus re-
covered after the 50 min binding showed that same amount
of EBOV had bound to both treated and control cells (data
Figure 6. Electron micro-
scopic analysis of VLPs gener-
ated by EBOV GP and VP40.
Particles obtained by ultracen-
trifugation of the supernatants of
293T cells transfected with
Ebola GPVP40 were nega-
tively stained with uranyl-acetate
to reveal the ultrastructure (A), or
stained with anti-EBOV-GP
mAb followed by Immunogold
rabbit anti–mouse Ab (B), and
analyzed by electron micros-
copy. The length of each parti-
cle is indicated in m. (C) 293T
cells transfected with Ebola
GPVP40 were immunogold-
stained for Ebola GP, fixed, cut,
and analyzed by electron micros-
copy. The picture depicts a typical
site of VLP release from the cells,
indicated by arrows. A magnifica-
tion of the site of VLP release is
also shown to better visualize the
gold staining on the particles.
Figure 7. Inhibition of Ebola infection by raft-disrupting agents filipin and nystatin. Vero
E6 cells were left untreated or treated for 30 min with 0.2 g/ml of filipin or 100 U/ml of
nystatin at 37C, washed extensively with PBS, and infected with EBOV at an MOI of 1. As
a control for lack of general toxicity and persistent effect on viral replication, upon treatment
with Filipin, cells were washed, and incubated in medium for 4 h before infection with
EBOV (Filipin→recovery). After 48 h supernatants were harvested and viral titers deter-
mined by plaque assay.
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not shown). Taken together, these data suggest that lipid
rafts play a critical role in the entry stage of Ebola infection.
 
Discussion
 
Our findings demonstrate that filoviruses utilize lipid
rafts as a platform for budding from the cells. We docu-
mented this phenomenon in reconstruction experiments
and in the process of live virus infections. Both after tran-
sient expression of filovirus GPs and in EBOV and MBGV
infected cells, we observed large patches of envelope GPs
in association with lipid rafts (Figs. 2 and 3). Our results
also demonstrate that the released virions incorporate the
raft-associated molecule GM1, but not TrfR, a protein ex-
cluded from lipid rafts (31). Using electron microscopy on
cells transfected with Ebola GP and matrix protein VP40,
we also demonstrate the site of release of EBOV-like parti-
cles to be localized in a small area of the plasma membrane
 

 
1 
 

 
m wide (Fig. 6 C). Therefore, such patches of rafts
appear to represent the site of filovirus assembly and bud-
ding. Electron microscopic studies show that virus budding
at the plasma membrane requires an accumulation of viral
components including nucleocapsid, matrix, and envelope
GP in an orchestrated manner, concurrent with structural
changes in the plasma membrane (39). This process is de-
pendent on a precise coordination of the involved compo-
nents (40). Thus, compartmentalization of viral assembly in
a specialized microdomain, such as rafts, with its ordered
architecture and selective array of molecules may increase
the efficiency of virus budding and decrease the frequency
of release of defective, noninfectious particles.
Besides acting as a coordination site for viral assembly,
rafts may have a profound impact on viral pathogenicity as
well as host immune response to viruses. Transfer of the in-
corporated molecules with signaling capabilities into newly
infected cells may affect the intracellular biochemical pro-
cesses in favor of a more efficient viral replication. Further-
more, selective enrichment of certain proteins such as ad-
hesion molecules can affect the efficiency of viral entry and
possibly virus tropism. Incorporation of GPI-anchored
proteins in the viral envelope such as inhibitors of comple-
ment pathway CD55 and CD59, which have been de-
tected in HIV virions (41), may help the virus evade the
complement-mediated lysis.
An important aspect of our study is the generation of ge-
nome-free filovirus-like particles. Our biochemical data
show that the VLPs incorporate both Ebola GP and matrix
protein VP40, as well as raft-associated ganglioside M1,
similar to the results obtained with live virus infections
(Fig. 4). A striking morphological similarity between these
VLPs and live filoviruses was observed in electron micro-
scopic studies (Fig. 6). These findings have several impor-
tant implications. While several viral matrix proteins sup-
port the formation of VLPs, Ebola VP40 seems to be
unique in that it requires the expression of envelope GP
for efficient formation of particles. Recently, Timmins et
al. reported that a small fraction of transfected VP40 could
be detected in culture supernatants in association with fila-
mentous particles (42). While we detected VP40 in the su-
pernatants of transfected 293T cells, electron microscopic
analysis revealed that the protein was associated with un-
structured membrane fragments. In multiple experiments,
filamentous particles were only observed when both VP40
and GP were concurrently expressed. These findings imply
that the driving force for the assembly and release of
EBOV may be the interaction between GP and matrix
protein, as suggested previously (1). Ebola VP40 has an
NH
 
2
 
-terminal and a COOH-terminal domain, the latter
being involved in membrane localization (43). Removal of
most of the COOH-terminal domain induces hexameriza-
tion of the protein, the multimeric form believed to be in-
volved in viral assembly (44). While our data show that the
majority of VP40 is membrane associated, we were unable
to detect VP40 in the rafts when expressed independently
(data not shown). Our attempts to detect VP40 in the lipid
rafts in the presence of GP was hampered by the efficient
release of the proteins in the supernatants resulting in
hardly detectable cellular levels of VP40 (Fig. 3). However,
given the incorporation of GM1 in the VP40-containing
VLPs, it is reasonable to speculate that a transient associa-
tion of VP40 with lipid rafts takes place in the cells. It is
possible that association of VP40 with GP drives VP40 into
the rafts. Since a fraction of GPs is outside the rafts (Fig. 1),
probably in a dynamic exchange with the rafts, this pool of
GPs might be involved in the initial interaction with
VP40. This interaction and subsequent movement to the
rafts may, at the same time, induce a conformational
change in VP40 resulting in dissociation of the COOH-
terminal domain from the nonraft membrane and thus re-
moving the constraints on the formation of VP40 hexamers
required for viral assembly. Detailed studies are underway
to test this model. In this regard, the successful generation
of VLPs by ectopic expression of viral proteins provides a
safe approach for the study of the steps involved in filovirus
assembly and budding without the restrictions of biosafety
level-4 laboratories.
VLPs could be an excellent vehicle for antigen delivery,
thus useful as a vaccination strategy (45, 46). Different types
of recombinant HIV-1 virus-like particles have been
shown to not only trigger the induction of neutralizing an-
tibodies but also induce HIV-specific CD8
 

 
 CTL re-
sponses in preclinical studies (46). Therefore, VLPs are ca-
pable of mobilizing different arms of the adaptive immune
system. Given the importance of both cellular and humoral
immune response for protection against Ebola (27, 47),
filovirus-based VLPs, alone or in combination with DNA
vaccination, may represent a good vaccine candidate. We
are currently investigating the capability of Ebola and Mar-
burg VLPs to elicit an immune response. Another potential
use of VLPs is in the delivery of foreign antigens. Parvovi-
rus-like particles have been engineered to express foreign
polypeptides, resulting in the production of large quantities
of highly immunogenic peptides, and to induce strong an-
tibody, Th cell, and CTL responses (46). Given the com-
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partmentalized release of VLPs through rafts, artificial tar-
geting of antigens to lipid rafts by introduction of dual
acylation signals may result in their enrichment in filovirus-
based VLPs, providing a potential novel strategy for deliv-
ery of a variety of antigens.
VLPs are also valuable research tools. Mutational analysis
of the proteins involved in filovirus release can be per-
formed using VLP formation as a quick read-out. Our
VLPs express the envelope GP in addition to the matrix
protein and can therefore be also used for detailed study of
the steps involved in the fusion and entry of EBOV and
MBGV by circumventing the restrictions of working under
biosafety level-4 conditions.
Most enveloped viruses use a specific interaction be-
tween their GPs and cell surface receptors to initiate the at-
tachment to cells and subsequent fusion. Organization of
viral receptors in the ordered environment of lipid rafts
may facilitate the virus binding through its multimeric GP,
promote lateral assemblies at the plasma membrane re-
quired for productive infections, concentrate the necessary
cytosolic and cytoskeletal components, and enhance the fu-
sion process by providing energetically favorable condi-
tions. It is intriguing that the HIV receptor CD4 (14), its
coreceptor CXCR4 (26), as well as molecules favoring
HIV infection such as glycosphingolipids (9, 48), and
CD44 (17, 49) all reside in lipid rafts. Our data suggest that
filoviruses use lipid rafts as a gateway for entry into cells.
This may relate to the presence of the filovirus receptor(s)
in these microdomains. Recently, it has been demonstrated
that folate receptor-
 

 
 can function as a cellular cofactor for
filoviruses (50). Interestingly, folate receptor-
 

 
 is a GPI-
anchored protein shown to reside in rafts (51). Thus, rafts
may be crucial for viral entry by concentrating the receptor
for filovirus GPs. Our finding that disruption of lipid rafts
can interfere with filovirus entry suggests that the integrity
of these compartments or their molecular components may
be potential therapeutic targets against Ebola and Marburg
infections. Further characterization of the raft composition
during host-virus interaction, for instance by proteomic
analysis, will help to identify such potential targets.
In summary, our findings shed new light on the molecu-
lar mechanisms involved in filovirus entry as well as assem-
bly and budding. Much deeper understanding of these
mechanisms is needed for successful design of efficacious
therapeutic and vaccination strategies. However, identifica-
tion of rafts as a gateway for cellular trafficking of Ebola and
Marburg viruses and generation of Ebola VLPs are impor-
tant steps toward this goal.
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